Cynomolgus DPP4 / DPPIV / CD26 Protein (Fc Tag)
DPP4
- 100ug (NPP4425) Please inquiry
| Catalog Number | P90180-C01H |
|---|---|
| Organism Species | Cynomolgus |
| Host | Human Cells |
| Synonyms | DPP4 |
| Molecular Weight | The recombinant cynomolgus DPP4 is a disulfide-linked homodimer. The reduced monomer comprises 993 amino acids and has a calculated molecular mass of 112.9 KDa.The apparent molecular mass of the protein is approximately 113 KDa in SDS-PAGE. |
| predicted N | Glu |
| SDS-PAGE |  |
| Purity | > 90 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the cynomolgus DPP4 (F6VRB0) (Asp34-Pro766) was expressed with the Fc region of human IgG1 at the C-terminus. |
| Bio-activity | Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-AMC(GP-AMC). The specific activity is > 3, 000 pmoles/min/μg. |
| Research Area | Microbiology |Pathogenic microorganism |viruses |animal virus |Virus infection associated |Virus host receptor | |
| Formulation | Lyophilized from sterile 25 mM MES, 0.7 M NaCl, pH 4.9. 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes. |
| Reference |